SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-16-011381
Filing Date
2016-03-21
Accepted
2016-03-21 12:51:25
Documents
4
Period of Report
2016-04-27
Effectiveness Date
2016-03-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2227785zdef14a.htm DEF 14A 328497
2 G59182BEI001.GIF g59182bei001.gif GRAPHIC 59570
3 G59182BEI002.GIF g59182bei002.gif GRAPHIC 35924
4 G279737.JPG g279737.jpg GRAPHIC 6436
  Complete submission text file 0001047469-16-011381.txt   470452
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37449 | Film No.: 161518220
SIC: 2834 Pharmaceutical Preparations